Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis

Ikuo Hirano*, Marc E. Rothenberg, Sandra Zhang, Claudia De Oliveira, Christina M. Charriez, Karin S. Coyne, Elizabeth Dansie Bacci, Evan S. Dellon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


INTRODUCTION:The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study.METHODS:Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo.RESULTS:A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079).DISCUSSION:Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.

Original languageEnglish (US)
Pages (from-to)744-747
Number of pages4
JournalAmerican Journal of Gastroenterology
Issue number4
StatePublished - Apr 1 2023

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis'. Together they form a unique fingerprint.

Cite this